Humana Inc. (NYSE: HUM) closed the day trading at $317.00 up 1.24% from the previous closing price of $313.11. In other words, the price has increased by $+3.89 from its previous closing price. On the day, 1299306 shares were traded. HUM stock price reached its highest trading level at $318.80 during the session, while it also had its lowest trading level at $310.72.
Ratios:
For a better understanding of HUM, let’s look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.75 whereas as Long-Term Debt/Eq ratio is at 0.66.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on April 02, 2024, Downgraded its rating to Neutral and sets its target price to $342 from $470 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 20 ’24 when Mesquita Jorge S. bought 545 shares for $367.09 per share. The transaction valued at 200,066 led to the insider holds 2,578 shares of the business.
Diamond Susan M sold 4,156 shares of HUM for $2,187,226 on May 04 ’23. The Chief Financial Officer now owns 3,931 shares after completing the transaction at $526.28 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUM now has a Market Capitalization of 38.21B and an Enterprise Value of 45.53B. As of this moment, Humana’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.99, and their Forward P/E ratio for the next fiscal year is 13.64. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 7.18. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.36 while its Price-to-Book (P/B) ratio in mrq is 2.38. Its current Enterprise Value per Revenue stands at 0.43.
Stock Price History:
Over the past 52 weeks, HUM has reached a high of $541.21, while it has fallen to a 52-week low of $299.23. The 50-Day Moving Average of the stock is 352.33, while the 200-Day Moving Average is calculated to be 444.06.
Shares Statistics:
Over the past 3-months, HUM traded about 2.14M shares per day on average, while over the past 10 days, HUM traded about 2.29M shares per day. A total of 122.22M shares are outstanding, with a floating share count of 120.12M. Insiders hold about 0.35% of the company’s shares, while institutions hold 94.56% stake in the company. Shares short for HUM as of Mar 15, 2024 were 2.57M with a Short Ratio of 1.20, compared to 2.16M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.13% and a Short% of Float of 2.13%.
Dividends & Splits
HUM’s forward annual dividend rate is 3.54, up from 3.54 a year ago. Against a Trailing Annual Dividend Yield of 1.13%, it implies a Forward Annual Dividend Yield of 1.12%. The stock’s 5-year Average Dividend Yield is 0.67. The current Payout Ratio is 17.70% for HUM, which recently paid a dividend on Apr 26, 2024 with an ex-dividend date of Mar 27, 2024. Stock splits for the company last occurred on Aug 01, 1991 when the company split stock in a 3:2 ratio.
Earnings Estimates
Current recommendations for the stock of the company come from 19 analysts. On average, analysts expect EPS of $6.12 for the current quarter, with a high estimate of $8.11 and a low estimate of $5.76, while EPS last year was $9.38. The consensus estimate for the next quarter is $5.81, with high estimates of $7.51 and low estimates of $4.31.
Analysts are recommending an EPS of between $18.84 and $15.94 for the fiscal current year, implying an average EPS of $16.36. EPS for the following year is $23.37, with 21 analysts recommending between $26.24 and $19.
Revenue Estimates
16 analysts predict $28.45B in revenue for the current quarter. It ranges from a high estimate of $29.6B to a low estimate of $27.44B. As of the current estimate, Humana Inc.’s year-ago sales were $25.65B, an estimated increase of 10.90% from the year-ago figure. For the next quarter, 16 analysts are estimating revenue of $28.03B, an increase of 8.90% less than the figure of $10.90% in the same quarter last year. There is a high estimate of $28.61B for the next quarter, whereas the lowest estimate is $27.39B.
A total of 17 analysts have provided revenue estimates for HUM’s current fiscal year. The highest revenue estimate was $113.71B, while the lowest revenue estimate was $108.91B, resulting in an average revenue estimate of $111.88B. In the same quarter a year ago, actual revenue was $102.64B, up 9.00% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $115.98B in the next fiscal year. The high estimate is $123.94B and the low estimate is $107.78B. The average revenue growth estimate for next year is up 3.70% from the average revenue estimate for this year.
